ÇѸ²´ëÇб³ Àǰú´ëÇÐ Ç÷¾×Á¾¾ç³»°ú
2010³â09¿ù10ÀÏ Friday
¿ÃÇØ ½ÃÀÛÇÑÁö 253Àϰ
(69.32 percent Áö³²)
·Î ±× ÀÎ
¾ÆÀ̵ð :
¾ÏÈ£ :
ȸ¿ø°¡ÀÔ
¾ÏÈ£ºÐ½Ç
¢Ã
Ç÷¾×Á¾¾ç³»°ú ¼Ò°³
¢Ã
Ç÷¾×Á¾¾çÇÐ ÅëÇÕ°ÀÇ
¢Ã
°Ô½ÃÆÇ
¢Ã
±³À° ÀÚ·á
¢Ã
¿¬±¸ ÀÚ·á
¢Ã
Áø·á ÀÚ·á
¢Ã
¸µÅ©
[Á¢¼ÓÅë°è]
¿À´Ã¹æ¹®ÀÚ:
127
¾îÁ¦¹æ¹®ÀÚ:
169
Àüü¹æ¹®ÀÚ:
181,138
ÇöÀçÁ¢¼ÓÀÚ:
4
Ãִ뵿½ÃÁ¢¼ÓÀÚ:
90
ÃÖ´ë¹æ¹®ÀÚ:
1,090
°øÁö»çÇ× ¹× ÀÚÀ¯°Ô½ÃÆÇ
more
[±èÁ¤ÇÑ] ±³¿øº° ´ã´çÁúȯ
[±èÁ¤ÇÑ] ±³¿øº° ¾÷¹«
[±èÁ¤ÇÑ] À̱ټ® ±³¼ö´Ô °¨»çÇÕ´Ï´Ù.
[¾ÈÁø¼®] IIP CRF ¿Ã·ÁÁÖ¼¼¿ä.
[Á¤ÁÖ¿µ] Çлý °ÀÇ¿¡ ´ëÇÑ Àǰ߰ú Àü°øÀÇ Áöħ¼ºÎºÐ
ÅëÇÕ °ÀÇ ¹× Ç÷¾×Á¾¾çÇÐ ±³À° °ü·Ã ÀÚ·á
more
[¤µ¤Ó Ƽ·£µå] ½ÃƼ·£µå.Ä«¤¸¤Ó ³ë,ctct777.tk
[Á¤¹Ì¿µ] ·ê·¿°ÔÀÓ»çÀÌÆ®
[»ç¶û¿¹°¨] ¼ºÀε¿¿µ»ó´Ù¿î
[¸±°ÔÀÓ] ¿Â¶óÀÎÀÇ ¸ðµç ¸±°ÔÀÓ ÃÑÁýÇÕ »çÀÌÆ®
http://m77.co2.in/
[¼ºÀϵ¿] Ȳ±Ý¼º°ÔÀÓ»çÀÌÆ®
Ç÷¾×Á¾¾çÇÐ ¿¬±¸ ÀÚ·á
more
[±èÁ¤ÇÑ] Alimta+Carbo as 2nd-line chemotherapy in NSCLC
[±ÇÁ¤Çý] fractionated docetaxel and cisplatin in NSCLC(°¡Á¦)_CRF
[±ÇÁ¤Çý] fractionated docetaxel and cisplatin in NSCLC(°¡Á¦)_Àӻ󿬱¸½Åû¼
[±ÇÁ¤Çý] fractionated docetaxel and cisplatin in NSCLC(°¡Á¦)_protocol and ÇÇÇèÀÚ µ¿ÀǼ
[±ÇÁ¤Çý] °¢º´¿øÀÇ °ø½Ä ¿µ¹® Ç¥±âÀÔ´Ï´Ù.
Ç÷¾×Á¾¾çÇÐ Áø·á ÀÚ·á
more
[À̱ټ®] °ñ¼öÀ̽ÄÈÄ immunization
[À̱ټ®] Rituximab º¸Çè ±âÁØ 2004. 10. 1.ÀÏÀÚ
[À̱ټ®] ÀڱðæºÎ¾Ï¿¡ cisplatin-concurrent RT ¿ë¹ý ±Þ¿©¹üÀ§ Å뺸 ¾È³»
[À̱ټ®] irinotecan º¸Çè ±âÁØ
[À̱ټ®] interferon alpha-2a, 2b º¸Çè ±âÁØ
Copyright ¨Ï 2004
Hematology and Medical Oncology, Hallym University
. All rights reserved.
ÿ